Oral Tirzepatide — The Future of Weight Loss Pills
Ben Synth explores orforglipron, Eli Lilly's new weight loss pill completing Phase 3 trials with 12.4% body weight reduction. He clarifies widespread confusion: this isn't oral tirzepatide but a different molecule entirely. With potential $50/month Medicare pricing and FDA approval expected in 2026, orforglipron could democratize obesity treatment beyond expensive injections. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI.
4 episodios
Comentarios
0Sé la primera persona en comentar
¡Regístrate ahora y únete a la comunidad de Oral Tirzepatide — The Future of Weight Loss Pills!